Novel alpha radiopharmaceutical therapy shows promise in early-phase prostate cancer trial
A new alpha-emitting radiopharmaceutical therapy (RPT) for advanced prostate cancer was well tolerated, with no dose-limiting toxicities observed, and showed encouraging signs of antitumor activity, according to a trial published in The Journal of Nuclear Medicine's Late-Breaking Fast Track.
Read original article on Medical Xpress - latest medical and health news stories →Related news
-
Workplace ergonomics may do little to ease arm, neck or shoulder pain
United Kingdom
-
Low vitamin B12 is linked to heart disease. Supplements tell a different story
United Kingdom
-
CT scans linked vitamin D levels to fat within muscles after bariatric surgery
United Kingdom
-
Needle-free Strep A vaccine triggers local and bodywide immune responses in mice
United Kingdom
-
Wearable EEG patch records stable brain signals over 24 hours, including sleep
United Kingdom
-
How socioeconomic factors affect outcomes in this deadly cancer
United Kingdom
-
Most adults with obesity did not meet food noise criteria in US survey
United Kingdom
-
Autistic women experience more severe menopausal symptoms, study confirms
United Kingdom